WHO Drug Information, Vol. 16, No. 1, 2002                                                   Recommended INN: List 47




International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names
(Rec. INN): List 47
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International
Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not
imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (185) and Recommended (145) International Nonproprietary Names can be found in Cumulative
List No. 10, 2002 (available in CD-ROM only).


Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES
(DCI Rec): Liste 47
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations
communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60,
3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisises par lOrganisation
mondiale de la Santé en tant que dénominations communes internationales recommandées. Linclusion dune dénomination
dans les listes de DCI recommandées nimplique aucune recommandation en vue de lutilisation de la substance
correspondante en médecine ou en pharmacie.
On trouvera dautres listes de Dénominations communes internationales proposées (185) et recommandées (145)
dans la Liste récapitulative No. 10, 2002 (disponible sur CD-ROM seulement ).


Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS
(DCI Rec.): Lista 47
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a
continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La
inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación
alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (185) y Recomendadas (145) se encuentran
reunidas en Cumulative List No. 10, 2002 (disponible sólo en CD-ROM).


                                                                                                                        81
Recommended INN: List 47                                                                 WHO Drug Information, Vol. 16, No. 1, 2002




Latin, English, French, Spanish:
Recommended INN         Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée       Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada       Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada



acidum gadocoleticum
gadocoletic acid                     trihydrogen [3β-[[(4S)-4-[bis[2-[bis[(carboxy-κO)methyl]amino-κN]ethyl]amino-
                                     κN]-4-(carboxy-κO)butanoyl]amino]-12α-hydroxy-5β-cholan-24-oato(6-)]=
                                     gadolinate(3-)

acide gadocolétique                  trihydrogéno[3β-[[(4S)-4-[bis[2-[bis[(carboxy-κO)méthyl]amino-N]éthyl]amino-
                                     κN]-4-(carboxy-κO)butanoyl]amino]-12α-hydroxy-5β-cholan-24-oato(6-)]=
                                     gadolinate(3-)

ácido gadocolético                   trihidrógeno[3β-[[(4S)-4-[bis[2-[bis[(carboxi-κO)metil]amino-κN]etil]amino-κN]-
                                     4-(carboxi-κO)butanoil]amino]-12α-hidroxi-5β-colan-24-ato(6-)]gadolinato(3-)

                                     C41H63GdN4O14


                                                                                                          H3 C H
                                                                                                      H
                                                                                                 HO       CH3          CO2H
                                                                                                                   H
                                                                                             CH3      H
                                                                              O
                                                                     H                            H       H
                                     2H+                  -
                                                              O 2C
                                                                                  N
                                                                                  H H        H
                                       -                             N                 -
                                           O2C        N                       N     CO2
                                                                         3+
                                            -                        Gd              -
                                                O2C                               CO2




afeletecanum
afeletecan                           camptothecin, ester with N-[[p-[(3-O-methyl-β-L-fucopyranosyl)oxy]phenyl]=
                                     thiocarbamoyl]-L-histidyl-L-valine

afélétécan                           (2S)-2-[[(2S)-3-(1H-imidazol-4-yl)-2-[[[[4-[(3-O-méthyl-6-désoxy-
                                     β-L-galactopyranosyl)oxy]phényl]amino]thiocarbonyl]amino]propanoyl]amino]-
                                     3-méthylbutanoate de (4S)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-
                                     1H-pyrano[3,4:6,7]indolizino[1,2-b]quinoléin-4-yle

afeletecán                           éster de la camptotecina con N-[[p-[(3-O-metil-β-L-fucopiranosil)oxi]fenil]=
                                     tiocarbamoil]-L-histidil-L-valina




82
WHO Drug Information, Vol. 16, No. 1, 2002                                                        Recommended INN: List 47




                                     C45H49N7O11S

                                                                                    O

                                                                               N              O

                                                                                                    O
                                                                       N
                                                                                    O     O CH3
                                                                               O
                                                               H       H
                                                    O          N       N                  H
                                                                                    N
                                             CH3 HO                                 H         CH3
                                                                   S           H
                                      HO                O                           H3C

                                             OCH3                          N       NH




alfimeprasum
alfimeprase                          [3-L-serine]fibrolase-(3-203)-peptide (fibrolase : fibrinolytic enzyme isolated
                                     from Agkistrodon contrix contrix venom)

alfiméprase                          [3-L-sérine]fibrolase-(3-203)-peptide (fibrolase : enzyme fibrinolytique extraite
                                     de venin dAgkistrodon contrix contrix)

alfimeprasa                          [3-L-serina]fibrolasa-(3-203)-péptido (fibrolasa : enzime fibrinolítica extraida
                                     de veneno de Agkistrodon contrix contrix)

                                     C985H1541N285O301S12


                                           SFPQRYVQ         LVIVADHRMN             TKYNGDSDKI           RQWVHQIVNT
                                      INEIYRPLNI            QFTLVGLEIW             SNQDLITVTS           VSHDTLASFG
                                      NWRETDLLRR            QRHDNAQLLT             AIDFDGDTVG           LAYVGGMCQL
                                      KHSTGVIQDH            SAINLLVALT             MAHELGHNLG           MNHDGNQCHC
                                      GANSCVMAAM            LSDQPSKLFS             DCSKKDYQTF           LTVNNPQCIL
                                      NKP




                                                                                                                        83
Recommended INN: List 47                                         WHO Drug Information, Vol. 16, No. 1, 2002




alicaforsenum
alicaforsen                2'-deoxy-(R)-P-thioguanylyl-(3'→5')-2'-deoxy-(R)-P-thiocytidylyl-
                           (3'→5')-2'-deoxy-(R)-P-thiocytidylyl-(3'→5')-2'-deoxy-(R)-P-thiocytidylyl-
                           (3'→5')-2'-deoxy-(R)-P-thioadenylyl-(3'→5')-2'-deoxy-(R)-P-thioadenylyl-
                           (3'→5')-2'-deoxy-(R)-P-thioguanylyl-(3'→5')-2'-deoxy-(R)-P-thiocytidylyl-
                           (3'→5')-(R)-P-thiothymidylyl-(3'→5')-2'-deoxy-(R)-P-thioguanylyl-
                           (3'→5')-2'-deoxy-(R)-P-thioguanylyl-(3'→5')-2'-deoxy-(R)-P-thiocytidylyl-
                           (3'→5')-2'-deoxy-(R)-P-thioadenylyl-(3'→5')-(R)-P-thiothymidylyl-
                           (3'→5')-2'-deoxy-(R)-P-thiocytidylyl-(3'→5')-2'-deoxy-(R)-P-thiocytidylyl-
                           (3'→5')-2'-deoxy-(R)-P-thioguanylyl-(3'→5')-(R)-P-thiothymidylyl-
                           (3'→5')-2'-deoxy-(R)-P-thiocytidylyl-(3'→5')-2'-deoxyadenosine
                           nonadecasodium salt

alicaforsen                2'-désoxy-(R)-P-thioguanylyl-(3'→5')-2'-désoxy-(R)-P-thiocytidylyl-
                           (3'→5')-2'-désoxy-(R)-P-thiocytidylyl-(3'→5')-2'-désoxy-(R)-P-thiocytidylyl-
                           (3'→5')-2'-désoxy-(R)-P-thioadénylyl-(3'→5')-2'-désoxy-(R)-P-thioadénylyl-
                           (3'→5')-2'-désoxy-(R)-P-thioguanylyl-(3'→5')-2'-désoxy-(R)-P-thiocytidylyl-
                           (3'→5')-(R)-P-thiothymidylyl-(3'→5')-2'-désoxy-(R)-P-thioguanylyl-
                           (3'→5')-2'-désoxy-(R)-P-thioguanylyl-(3'→5')-2'-désoxy-(R)-P-thiocytidylyl-
                           (3'→5')-2'-désoxy-(R)-P-thioadénylyl-(3'→5')-(R)-P-thiothymidylyl-
                           (3'→5')-2'-désoxy-(R)-P-thiocytidylyl-(3'→5')-2'-désoxy-(R)-P-thiocytidylyl-
                           (3'→5')-2'-désoxy-(R)-P-thioguanylyl-(3'→5')-(R)-P-thiothymidylyl-
                           (3'→5')-2'-désoxy-(R)-P-thiocytidylyl-(3'→5')-2'-désoxyadénosine
                           nonadécasodique

alicaforseno               2'-desoxi-(R)-P-tioguanilil-(3'→5')-2'-desoxi-(R)-P-tiocitidilil-
                           (3'→5')-2'-desoxi-(R)-P-tiocitidilil-(3'→5')-2'-desoxi-(R)-P-tiocitidilil-
                           (3'→5')-2'-desoxi-(R)-P-tioadenilil-(3'→5')-2'-desoxi-(R)-P-tioadenilil-
                           (3'→5')-2'-desoxi-(R)-P-tioguanilil-(3'→5')-2'-desoxi-(R)-P-tiocitidilil-
                           (3'→5')-(R)-P-tiotimidilil-(3'→5')-2'-desoxi-(R)-P-tioguanilil-(3'→5')-2'-desoxi-
                           (R)-P-tioguanilil-(3'→5')-2'-desoxi-(R)-P-tiocitidilil-(3'→5')-2'-desoxi-
                           (R)-P-tioadenilil-(3'→5')-(R)-P-tiotimidilil-(3'→5')-2'-desoxi-(R)-P-tiocitidilil-
                           (3'→5')-2'-desoxi-(R)-P-tiocitidilil-(3'→5')-2'-desoxi-(R)-P-tioguanilil-
                           (3'→5')-(R)-P-tiotimidilil-(3'→5')-2'-desoxi-(R)-P-tiocitidilil-
                           (3'→5')-2'-desoxiadenosina nonadecasódica

                           C192H225N75Na19O98P19S19


alilusemum
alilusem                   7-chloro-1-(2-methylbenzoyl)-2,3-dihydroquinolin-4(1H)-one
                           (E)-O-sulfooxime

alilusem                   (E)-O-sulfooxime de 7-chloro-1-(2-méthylbenzoyl)-2,3-dihydroquinoléin-
                           4(1H)-one

alilusem                   (E)-O-sulfooxima de 7-cloro-1-(2-metilbenzoil)-2,3-dihidroquinolin-4(1H)-ona

                           C17H15ClN2O5S

                                                        SO3H
                                                    O
                                                    N

                                         N

                               CH3   O

                                               Cl


84
WHO Drug Information, Vol. 16, No. 1, 2002                                                   Recommended INN: List 47




ambrisentanum
ambrisentan                          (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic
                                     acid

ambrisentan                          (+)-acide (2S)-2-[(4,6-diméthylpyrimidin-2-yl)oxy]-3-méthoxy-
                                     3,3-diphénylpropanoïque

ambrisentán                          (+)-ácido (2S)-2-[(4,6-dimetilpirimidin-2-il)oxi]-3-metoxi-3,3-difenilpropanoico

                                     C22H22N2O4


                                                     CO2H            CH 3
                                                             H   N
                                                         O
                                         H3CO
                                                                 N
                                                                     CH 3




amdoxovirum
amdoxovir                            [(2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol

amdoxovir                            [(2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-1,3-dioxolan-2-yl]méthanol

amdoxovir                            [(2R,4R)-4-(2,6-diamino-9H-purin-9-il)-1,3-dioxolan-2-il]metanol

                                     C9H12N6O3


                                                 NH2

                                                           N
                                             N

                                      H2N        N         N
                                                                 H
                                             HO        O

                                                             O
                                                     H




amelubantum
amelubant                            ethyl [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]benzyl]=
                                     oxy]phenyl](imino)methyl]carbamate

amélubant                            [[4-[[3-[[4-[1-(4-hydroxyphényl)-1-méthyléthyl]phénoxy]méthyl]benzyl]oxy]=
                                     phényl](imino)méthyl]carbamate déthyle

amelubant                            [[4-[[3-[[4-[1-(4-hidroxifenil)-1-metiletil]fenoxi]metil]bencil]oxi]fenil](imino)metil]=
                                     carbamato de etilo




                                                                                                                           85
Recommended INN: List 47                                                   WHO Drug Information, Vol. 16, No. 1, 2002




                           C33H34N2O5


                                            O       NH                                     H3C   CH3

                           H 3C        O        N
                                                H
                                                                   O                O                     OH




amotosalenum
amotosalen                 3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g][1]benzopyran-7-one

amotosalène                3-[(2-aminoéthoxy)méthyl]-2,5,9-triméthyl-7H-furo[3,2-g][1]benzopyran-7-one

amotosaleno                3-[(2-aminoetoxi)metil]-2,5,9-trimetil-7H-furo[3,2-g][1]benzopiran-7-ona

                           C17H19NO4


                                           O                   CH3

                           H 2N
                                      H3C
                                                O              O       O
                                                         CH3




bimatoprostum
bimatoprost                (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-
                           1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide

bimatoprost                (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phénylpent-
                           1-ényl]cyclopentyl]-N-éthylhept-5-énamide

bimatoprost                (Z)-7-[(1R,2R,3R,5S)-3,5-dihidroxi-2-[(1E,3S)-3-hidroxi-5-fenilpent-
                           1-enil]ciclopentil]-N-etilhept-5-enamida

                           C25H37NO4


                                  OH                                   H
                            H          H
                                                                       N   CH3

                                                                   O
                           HO          H
                                  H             H OH




86
WHO Drug Information, Vol. 16, No. 1, 2002                                              Recommended INN: List 47




caldaretum
caldaret                             5-methyl-2-(piperazin-1-yl)benzenesulfonic acid

caldaret                             acide 5-méthyl-2-(pipérazin-1-yl)benzènesulfonique

caldaret                             ácido 5-metil-2-(piperazin-1-il)bencenosulfónico

                                     C11H16N2O3S


                                      H3C               SO3H


                                                        N
                                                               NH




cipralisantum
cipralisant                          4-[(1R,2R)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1H-imidazole

cipralisant                          4-[(1R,2R)-2-(5,5-diméthylhex-1-ynyl)cyclopropyl]-1H-imidazole

cipralisant                          4-[(1R,2R)-2-(5,5-dimetilhex-1-inil)ciclopropil]-1H-imidazol

                                     C14H20N2


                                                H   H
                                        N
                                                                        CH 3
                                      HN
                                                                H 3C   CH3




darbepoetinum alfa
darbepoetin alfa                     [30-L-asparagine,32-L-thronine,87- L-valine,88-L-asparagine,
                                     90-L-threonine]erythropoietin (human)

darbépoétine alfa                    [30-L-asparagine,32-L-thréonine,87-L-valine,88-L-asparagine,
                                     90-L-thréonine]érythropoiétine humaine

darbepoetina alfa                    [30-L-asparagina,32-L-treonina,87- L-valina,88-L-asparagina,
                                     90-L-treonina]eritropoietina humana

                                     C800H1300N228O243S5



                                        APPRLICDSR             VLERYLLEAK      EAENITTGCN       ETCSLNENIT
                                        VPDTKVNFYA             WKRMEVGQQA      VEVWQGLALL       SEAVLRGQAL
                                        LVNSSQVNET             LQLHVDKAVS      GLRSLTTLLR       ALGAQKEAIS
                                        PPDAASAAPL             RTITADTFRK      LFRVYSNFLR       GKLKLYTGEA
                                        CRTGD


                                                                                                             87
Recommended INN: List 47                                               WHO Drug Information, Vol. 16, No. 1, 2002




drotrecoginum alfa (activatum)
drotrecogin alfa (activated)     blood coagulation factor XIV (human)

drotrécogine alfa (activé)       facteur XIV humain de coagulation sanguine

drotrecogina alfa (activada)     factor XIV de coagulación sanguínea (humano)

                                 C2071H3165N581O640S31




                                 ANSFLJJLRH              SSLJRJCIJJ        ICDFJJAKJI        FQNVDDTLAF
                                 WSKHVDGDQC              LVLPLEHPCA        SLCCGHGTCI        BGIGSFSCDC
                                                               *
                                 RSGWEGRFCQ              REVSFLNCSL    DNGGCTHYCL            EEVGWRRCSC
                                 APGYKLGDDL              LQCHPAVKFP    CGRPWKRMEK            KRSHL
                                                                                                         DTE
                                 DQEDQVDPRL              IDGKMTRRGD        SPWQVVLLDS        KKKLACGAVL
                                 IHPSWVLTAA              HCMDESKKLL    VRLGEYDLRR            WEKWELDLDI
                                              *
                                 KEVFVHPNYS              KSTTDNDIAL    LHLAQPATLS            QTIVPICLPD
                                                                                               *
                                 SGLAERELNQ              AGQETLVTGW    GYHSSREKEA            KRNRTFVLNF
                                         *
                                 IKIPVVPHNE              CSEVMSNMVS    ENMLCAGILG            DRQDACEGDS
                                 GGPMVASFHG              TWFLVGLVSW    GEGCGLLHNY            GVYTKVSRYL
                                 DWIHGHIRDK              EAPQKSWAP                           HO2C
                                                                               CO2H                      CO2H
                                 * glycosylation sites                HO        H                    H
                                 * sites de glycosylation
                                 * posiciones de glicosilación             N                   N
                                                                 B=                     J=
                                                                           H                   H
                                                                                 O                   O




ecalcidenum
ecalcidene                       1-[(5Z,7E,20S)-1α,3β-dihydroxy-9,10-secochola-5,7,10(19)-trien-
                                 24-oyl]piperidine

écalcidène                       1-[(5Z,7E,20S)-1α,3β-dihydroxy-9,10-sécochola-5,7,10(19)-trién-
                                 24-oyl]pipéridine

ecalcideno                       1-[(5Z,7E,20S)-1α,3β-dihidroxi-9,10-secocola-5,7,10(19)-trien-
                                 24-oil]piperidina




88
WHO Drug Information, Vol. 16, No. 1, 2002                                                     Recommended INN: List 47




                                     C29H45NO3


                                                    H3C H            O
                                                     CH3
                                                            H         N


                                                     H


                                                     CH2

                                      HO               OH
                                           H       H




efalizumabum
efalizumab                           immunoglobulin G1, anti-(human antigen CD11a) (human-mouse monoclonal
                                     hu1124 γ1-chain), disulfide with human-mouse monoclonal hu1124 light
                                     chain, dimer

éfalizumab                           immunoglobuline G1, anti-(antigène CD11a humain) (chaîne γ1 de lanticorps
                                     monoclonal de souris humanisé hu1124),dimère du disulfure avec la chaîne
                                     légère de lanticorps monoclonal de souris humanisé hu1124

efalizumab                           inmunoglobulina G1, anti-(antígeno CD11a humano) (cadena γ1 del anticuerpo
                                     monoclonal humanizado de ratón hu1124), dímero del disulfuro con la
                                     cadena ligera del anticuerpo monoclonal humanizado de ratón hu1124




enfuvirtidum
enfuvirtide                          acetyl-L-tyrosyl- L-threonyl-L-seryl- L-leucyl-L-isoleucyl- L-histidyl-L-seryl-
                                     L-leucyl-L-isoleucyl-L-α-glutamyl-L-α-glutamyl-L-seryl-L-glutaminyl-
                                     L-asparaginyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-lysyl-L-asparaginyl-
                                     L-α-glutamyl-L-glutaminyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-leucyl-
                                     L-α-aspartyl- L-lysyl-L-tryptophyl-L-alanyl- L-seryl-L -leucyl-L-tryptophyl-
                                     L-asparaginyl-L-tryptophyl-L-phenylalaninamide


enfuvirtide                          acétyl-L-tyrosyl- L-thréonyl-L-séryl- L-leucyl-L-isoleucyl- L-histidyl-L-séryl-
                                     L-leucyl-L-isoleucyl-L-α-glutamyl-L-α-glutamyl-L-séryl-L-glutaminyl-
                                     L-asparaginyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-lysyl-L-asparaginyl-
                                     L-α-glutamyl-L-glutaminyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-leucyl-
                                     L-α-aspartyl- L-lysyl-L-tryptophyl-L-alanyl- L-séryl-L -leucyl-L-tryptophyl-
                                     L-asparaginyl-L-tryptophyl-L-phénylalaninamide


enfuvirtida                          acetil-L-tirosil-L-treonil-L-seril-L-leucil-L-isoleucil-L-histidil-L-seril-L-leucil-
                                     L-isoleucil-L-α-glutamil-L-α-glutamil-L-seril-L-glutaminil-L-asparaginil-L-glutaminil-
                                     L-glutaminil-L-α-glutamil-L-lisil-L-asparaginil-L-α-glutamil-L-glutaminil-L-α-glutamil-
                                     L-leucil-L-leucil-L-α-glutamil-L-leucil-L-α-aspartil-L-lisil-L-triptofil-L-alanil-L-seril-
                                     L-leucil-L-triptofil-L-asparaginil-L-triptofil-L-fenilalaninamida




                                                                                                                             89
Recommended INN: List 47                                                      WHO Drug Information, Vol. 16, No. 1, 2002




                           C204H301N51O64



                           H3C
                                    Tyr     Thr     Ser     Leu     Ile His     Ser    Leu    Ile   Glu   Glu   Ser
                                                                                                    10
                               O
                           Gln Asn        Gln     Gln     Glu   Lys     Asn    Glu    Gln    Glu    Leu   Leu   Glu
                                                                               20
                           Leu    Asp     Lys     Trp     Ala     Ser   Leu     Trp   Asn     Trp   Phe NH2
                                                           30




epafipasum
epafipase                  2-acetyl-1-alkyl-sn-glycero-3-phosphocholine deacetylase-(6-400)-peptide
                           (human)

épafipase                  désacétylase-(6-400)-peptide (humaine) de la 2-acétyl-1-alkyl-sn-glycéro-
                           3-phosphocholine

epafipasa                  1-O-alquil-2-acetil-sn-glicero-3-fosfocolina 6-400-desacetilasa (humana)

                           C2016H3107N545O586S14



                           AAASFGQTKI               PRGNGPYSVG                CTDLMFDHTN             KGTFLRLYYP
                           SQDNDRLDTL               WIPNKEYFWG                LSKFLGTHWL             MGNILRLLFG
                           SMTTPANWNS               PLRPGEKYPL                VVFSHGLGAF             RTLYSAIGID
                           LASHGFIVAA               VEHRDRSASA                TYYFKDQSAA             EIGDKSWLYL
                           RTLKQEEETH               IRNEQVRQRA                KECSQALSLI             LDIDHGKPVK
                           NALDLKFDME               QLKDSIDREK                IAVIGHSFGG             ATVIQTLSED
                           QRFRCGIALD               AWMFPLGDEV                YSRIPQPLFF             INSEYFQYPA
                           NIIKMKKCYS               PDKERKMITI                RGSVHQNFAD             FTFATGKIIG
                           HMLKLKGDID               SNVAIDLSNK                ASLAFLQKHL             GLHKDFDQWD
                           CLIEGDDENL               IPGTNINTTN                QHIMLQNSSG             IEKYN




epoetinum delta
epoetin delta              1-165-erythropoietin (human HMR4396), glycoform δ

époétine delta             1-165-érythropoiétine (humaine HMR4396), glycoforme δ

epoetina delta             1-165-eritropoietina (humana HMR4396), glicoforma δ




90
WHO Drug Information, Vol. 16, No. 1, 2002                                                        Recommended INN: List 47




                                     C809H1301N229O240S5


                                                                                    *                          *
                                      APPRLICDSR            VLERYLLEAK           EAENITTGCA             EHCSLNENIT
                                      VPDTKVNFYA            WKRMEVGQQA              VEVWQGLALL          SEAVLRGQAL
                                         *
                                      LVNSSQPWEP            LQLHVDKAVS           GLRSLTTLLR             ALGAQKEAIS
                                           *
                                      PPDAASAAPL            RTITADTFRK           LFRVYSNFLR             GKLKLYTGEA
                                      CRTGD
                                         * : glycosylation sites / sites de glycosylation / posiciones de glicosilación




erlotinibum
erlotinib                            N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine

erlotinib                            N-(3-éthynylphényl)-6,7-bis(2-méthoxyéthoxy)quinazolin-4-amine

erlotinib                            N-(3-etinilfenil)-6,7-bis(2-metoxietoxi)quinazolin-4-amina

                                     C22H23N3O4


                                      H3 C             O             N
                                             O
                                             O                           N
                                      H3 C             O
                                                                                      CH
                                                                  HN




febuxostatum
febuxostat                           2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid

fébuxostat                           acide 2-[3-cyano-4-(2-méthylpropoxy)phényl]-4-méthylthiazole-
                                     5-carboxylique

febuxostat                           ácido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxílico

                                     C16H16N2O3S

                                                                         CH3
                                                                 N
                                                                             CO2H
                                                                     S
                                      H3C
                                                   O
                                             CH3           CN




                                                                                                                          91
Recommended INN: List 47                                            WHO Drug Information, Vol. 16, No. 1, 2002




feloprentanum
feloprentan                (2S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-
                           3,3-diphenylpropanoic acid

féloprentan                acide (2S)-3-[2-(3,4-diméthoxyphényl)éthoxy]-2-[(4,6-diméthylpyrimidin-
                           2-yl)oxy]-3,3-diphénylpropanoïque

feloprentán                ácido (2S)-3-[2-(3,4-dimetoxifenil)etoxi]-2-[(4,6-dimetilpirimidin-2-il)oxi]-
                           3,3-difenilpropanoico

                           C31H32N2O6

                                                         CO2H         CH3
                                                              H N
                                                          O
                                                     O
                                                                N
                           H3CO
                                                                      CH3

                                 H3CO




finafloxacinum
finafloxacin               (-)-8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-
                           1,4-oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

finafloxacine              (-)-acide 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-
                           hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoléine-
                           3-carboxylique

finafloxacino              (-)-ácido 8-ciano-1-ciclopropil-6-fluoro-7-[(4aS,7aS)-hexahidropirrolo[3,4-b]-
                           1,4-oxazin-6(2H)-il)-4-oxo-1,4-dihidroquinolina-3-carboxílico

                           C20H19FN4O4


                                     NH H
                                                CN
                             O
                                            N        N
                                 H

                                            F            CO2H
                                                     O


gadomelitolum
gadomelitol                hydrogen [2,2',2',2'-[1,4,7,10-tetraazacyclododecane-1,4,7,10-triyl]tetrakis=
                           [5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl-
                           2,4,6-tribromo]carbamoyl]phenyl]amino]-2-oxoethyl]carbamoyl]phenyl]=
                           carbamoyl]phenyl]amino]-2-oxoethyl]amino]-5-oxopentanoato](4-)]=
                           gadolinate(1-)

gadomélitol                hydrogéno-[2,2',2',2'-[1,4,7,10-tétraazacyclododécane-1,4,7,10-triyl]tétrakis
                           [5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl-
                           2,4,6-tribromo]carbamoyl]phényl]amino]-2-oxoéthyl]carbamoyl]phényl]=
                           carbamoyl]phényl]amino]-2-oxoéthyl]amino]-5-oxopentanoato](4-)]=
                           gadolinate(1-)


92
WHO Drug Information, Vol. 16, No. 1, 2002                                                          Recommended INN: List 47




gadomelitol                          hidrógeno-[2,2',2',2'-[1,4,7,10-tetraazaciclododecano-1,4,7,10-triil]tetrakis=
                                     [5-[[2-[[4-[[4-[[2-[[3,5-bis[bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahidroxihexil-
                                     2,4,6-tribromo]carbamoil]fenil]amino]-2-oxoetil]carbamoil]fenil]carbamoil]fenil]=
                                     amino]-2-oxoetil]amino]-5-oxopentanoato](4-)]gadolinato(1-)

                                     C228H313Br12GdN32O116


                                                 R               R                                                      H
                                                                                                                        N     O
                                      -                                 -
                                          O2C                        CO2                            H
                                                     N       N
                                                                                                    N
                                                         Gd 3+                                                                NH

                                                     N       N                    O                      O
                                      HO2C                           CO2-                                                          O
                                                                                      HN                                H2C
                                                 R               R

                                                                            OH   OH        O   NH            OH    OH
                                                                                          Br        Br
                                                R- =        HO                                                                OH
                                                                      OH OH           N                  N     OH OH
                                                                        OH                                       OH
                                                                                    O          Br   O
                                                            HO                    OH                 HO                       OH
                                                                      OH     OH                                OH   OH




garnocestimum
garnocestim                          5-73-macrophage inflammatory protein 2α (human gene gro2)

garnocestim                          CXC chimiokine GROβ-(5-73)-peptide (GROβ : protéine inflammatoire humaine
                                     sécrétée par les macrophages)

garnocestim                          CXC quimiokina GROβ-(5-73)-péptido (GROβ : proteína inflamatoria humana
                                     secretada por los macrófagos)

                                     C325H557N97O95S6


                                                TELRCQ           CLQTLQGIHL               KNIQSVKVKS         PGPHCAQTEV
                                      IATLKNGQKA                 CLNPASPMVK               KIIEKMLKNG         KSN




gefitinibum
gefitinib                            N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-
                                     4-yl)propoxy]quinazolin-4-amine

géfitinib                            N-(3-chloro-4-fluorophényl)-7-méthoxy-6-[3-(morpholin-
                                     4-yl)propoxy]quinazolin-4-amine

gefitinib                            N-(3-cloro-4-fluorofenil)-7-metoxi-6-[3-(morfolin-4-il)propoxi]quinazolin-
                                     4-amina



                                                                                                                                       93
Recommended INN: List 47                                             WHO Drug Information, Vol. 16, No. 1, 2002




                           C22H24ClFN4O3


                                            H 3CO            N

                                                                 N
                                  N             O
                           O                                HN             Cl


                                                                           F



ingliforibum
ingliforib                 5-chloro-N-[(1S,2R)-1-benzyl-3-(cis-3,4-dihydroxypyrrolidin-1-yl)-
                           2-hydroxy-3-oxopropyl]-1H-indole-2-carboxamide

ingliforib                 5-chloro-N-[(1S,2R)-1-benzyl-3-(cis-3,4-dihydroxypyrrolidin-1-yl)-
                           2-hydroxy-3-oxopropyl]-1H-indole-2-carboxamide

ingliforib                 5-cloro-N-[(1S,2R)-1-bencil-3-(cis-3,4-dihidroxipirrolidin-1-il)-2-hidroxi-
                           3-oxopropil]-1H-indol-2-carboxamida

                           C23H24ClN3O5




                                            O       H   O
                                      H
                                      N                               OH
                                                N           N
                                                H   H OH              H
                                                                     OH
                                                                 H
                           Cl




ipravacainum
ipravacaine                (2RS)-1-(cyclopropylmethyl)-2',6'-dimethyl-2-piperidinecarboxanilide

ipravacaïne                (2RS)-1-(cyclopropylméthyl)-N-(2,6-diméthylphényl)pipéridine-2-carboxamide

ipravacaína                (2RS)-1-(ciclopropilmetil)-N-(2,6-dimetilfenil)piperidina-2-carboxamida

                           C18H26N2O


                                CH3
                                      H H
                                      N                 and enantiomer
                                                N       et énantiomère
                                        O               y enantiómero
                                      CH3




94
WHO Drug Information, Vol. 16, No. 1, 2002                                                         Recommended INN: List 47




isegananum
iseganan                             L-arginylglycylglycyl-L-leucyl- L-cysteinyl-L -tyrosyl-L-cysteinyl-L -arginylglycyl-
                                     L-arginyl-L-phenylalanyl-L-cysteinyl-L-valyl- L-cysteinyl-L-valylglycyl-
                                     L-argininamide     cyclic (5→14),(7→12)-bis(disulfide)

iséganan                             (5→14),(7→12)-bis(disulfure cyclique) de L-arginyl-glycyl-glycyl-L-leucyl-
                                     L-cystéinyl-L-tyrosyl- L-cystéinyl-L-arginyl-glycyl- L-arginyl- L-phénylalanyl-
                                     L-cystéinyl-L-valyl-L-cystéinyl-L-valyl-glycyl-L-argininamide


iseganán                             (5→14),(7→12)-bis(disulfuro cíclico) de L-arginil-glicil-glicil-L-leucil-L-cisteinil-
                                     L-tirosil-L-cisteinil-L-arginil-glicil-L-arginil-L-fenilalanil-L-cisteinil-L-valil-L-cisteinil-
                                     L-valil-glicil-L-argininamida


                                     C78H126N30O18S4



                                      H Arg    Gly   Gly   Leu    Cys    Tyr   Cys    Arg    Gly   Arg   Phe    Cys

                                        Val   Cys    Val    Gly   Arg NH2




labetuzumabum
labetuzumab                          immunoglobulin G, anti-(human carcinoembryonic antigen) (human-mouse
                                     monoclonal hMN-14 γ-chain), disulfide with human-mouse monoclonal
                                     hMN-14 κ-chain, dimer

labétuzumab                          immunoglobuline G, anti-(antigène carcinoembryonnaire humain) (chaîne-γ de
                                     lanticorps monoclonal de souris humanisé hMN-14), dimère du disulfure avec
                                     la chaîne-κ de lanticorps monoclonal de souris humanisé hMN-14

labetuzumab                          inmunoglobulina G, anti-(antígeno carcinoembrionario humano) (cadena-γ del
                                     anticuerpo monoclonal humanizado de ratón hMN-14), dímero del disulfuro
                                     con la cadena-κ del anticuerpo monoclonal humanizado de ratón hMN-14




laniquidarum
laniquidar                           methyl 6,11-dihydro-11-[1-[2-[4-(-2-quinolylmethoxy)phenyl]ethyl]-
                                     4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate

laniquidar                           11-[1-[2-[4-(quinoléin-2-ylméthoxy)phényl]éthyl]pipéridin-4-ylidène]-
                                     6,11-dihydro-5H-imidazo[2,1-b][3]benzazépine-3-carboxylate de méthyle

laniquidar                           11-[1-[2-[4-(quinolin-2-ilmetoxi)fenil]etil]piperidin-4-ilideno]-6,11-dihidro-
                                     5H-imidazo[2,1-b][3]benzazepina-3-carboxilato de metilo




                                                                                                                                   95
Recommended INN: List 47                                                   WHO Drug Information, Vol. 16, No. 1, 2002




                           C37H36N4O3




                                  O         N

                                                N               N
                           H3 C   O

                                                                                   O
                                                                                        N




lapisteridum
lapisteride                N-[1-(4-methoxyphenyl)-1-methylethyl]-3-oxo-4-aza-5α-androst-1-ene-
                           17β-carboxamide

lapistéride                N-[1-(4-méthoxyphényl)-1-méthyléthyl]-3-oxo-4-aza-5α-androst-1-ène-
                           17β-carboxamide

lapisterida                N-[1-(4-metoxifenil)-1-metiletil]-3-oxo-4-aza-5α-androst-1-eno-
                           17β-carboxamida

                           C29H40N2O3


                                                        O   H       CH3
                                                            N
                                                    CH3              CH3
                                                            H
                                      CH3       H

                                        H           H
                           O      N                             OCH3
                                  H H




laquinimodum
laquinimod                 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-
                           3-carboxamide

laquinimod                 5-chloro-N-éthyl-4-hydroxy-1-méthyl-2-oxo-N-phényl-1,2-dihydroquinoléine-
                           3-carboxamide

laquinimod                 5-cloro-N-etil-4-hidroxi-1-metil-2-oxo-N-fenil-1,2-dihidroquinolina-
                           3-carboxamida




96
WHO Drug Information, Vol. 16, No. 1, 2002                                                        Recommended INN: List 47




                                     C19H17ClN2O3


                                                  CH3
                                                  N      O       CH3

                                                             N

                                        Cl        OH     O




laronidasum
laronidase                           8-L-histidine-α-L-iduronidase (human)

laronidase                           [8-L-histidine]-α-L-iduronidase humaine

laronidasa                           8-L-histidina-α-L-iduronidasa (humana)

                                     C3169H4854N901O884S12



                                      AEAPHLVHVD               AARALWPLRR              FWRSTGFCPP        LPHSQADQYV
                                      LSWDQQLNLA               YVGAVPHRGI              KQVRTHWLLE        LVTTRGSTGR
                                             *
                                      GLSYNFTHLD               GYLDLLRENQ              LLPGFELMGS       ASGHFTDFED
                                      KQQVFEWKDL               VSSLARRYIG              RYGLAHVSKW       NFETWNEPDH
                                             *
                                      HDFDNVSMTM               QGFLNYYDAC              SEGLRAASPA        LRLGGPGDSF
                                      HTPPRSPLSW               GLLRHCHDGT              NFFTGEAGVR        LDYISLHRKG
                                      ARSSISILEQ               EKVVAQQIRQ              LFPKFADTPI       YNDEADPLVG
                                                                                                        *
                                      WSLPQPWRAD               VTYAAMVVKV              IAQHQNLLLA       NTTSAFPYAL
                                                                                             *
                                      LSNDNAFLSY               HPHPFAQRTL              TARFQVNNTR        PPHVQLLRKP
                                                                                                   *
                                      VLTAMGLLAL               LDEEQLWAEV              SQAGTVLDSN        HTVGVLASAH
                                                                                            *
                                      RPQGPADAWR               AAVLIYASDD              TRAHPNRSVA       VTLRLRGVPP
                                      GPGLVYVTRY               LDNGLCSPDG              EWRRLGRPVF        PTAEQFRRMR
                                      AAEDPVAAAP               RPLPAGGRLT              LRPALRLPSL        LLVHVCARPE
                                      KPPGQVTRLR               ALPLTQGQLV              LVWSDEHVGS        KCLWTYEIQF
                                      SQDGKAYTPV               SRKPSTFNLF              VFSPDTGAVS        GSYRVRALDY
                                      WARPGPFSDP               VPYLEVPVPR              GPPSPGNP
                                         * : glycosylation sites / sites de glycosylation / posiciones de glicosilación

                                                 : disulfide / disulfure / disulfuro




                                                                                                                          97
Recommended INN: List 47                                         WHO Drug Information, Vol. 16, No. 1, 2002




lirimilastum
lirimilast                 2-(2,4-dichlorobenzoyl)-3-ureidobenzofuran-6-yl methanesulfonate

lirimilast                 méthanesulfonate de 2-(2,4-dichlorobenzoyl)-3-uréidobenzofuran-6-yle

lirimilast                 metanosulfonato de 2-(2,4-diclorobenzoil)-3-ureidobenzofuran-6-ilo

                           C17H12Cl2N2O6S


                                                     O      Cl
                                 O           O
                                     O
                           H3C   S
                                     O               NH          Cl

                                                 O        NH2




livaraparinum calcium
livaraparin calcium        calcium salt of a low molecular mass heparin that is obtained by nitrous acid
                           depolymerization of heparin from porcine intestinal mucosa; the majority of
                           the components have a 2-O-sulfo-α-L-idopyranosuronic acid structure at the
                           non-reducing end and a 6-O-sulfo-structure at the reducing end of their
                           chain; the mass-average molecular mass ranges between 3000 and 5000
                           with 75% is less than 8000; the degree of sulfatation is approximately 2 per
                           disaccharidic unit

livaraparine calcique      sel calcique dune héparine de basse masse moléculaire obtenue par
                           dépolymérisation, au moyen dacide nitreux, dhéparine de muqueuse
                           intestinale de porc ; la majorité des composants de la livaraparine calcique
                           possèdent une structure acide 2-O-sulfo-α-L-idopyranosuronique à
                           lextrémité non réductrice de leur chaîne et une structure 6-O-sulfatée à
                           lextrémité réductrice de leur chaîne ; la masse moléculaire relative moyenne
                           est de 3000 à 5000, 75% étant inférieur à 8000 ; le degré de sulfatation par
                           unité disaccharide est voisin de 2

livaraparina cálcica       sal cálcica de una heparina de baja masa molecular obtenida de heparina de
                           mucosa intestinal de cerdo por despolimerización con ácido nitroso; la mayoría
                           de los componentes de la livaraparina cálcica tienen ácido 2-O-sulfo-
                           α-L-idopiranosurónico en el extremo no reductor de la cadena y una
                           estructura 6-O-sulfatada en el extremo reductor de la cadena; la masa
                           molecular relativa media es de 3000 a 5000, siendo el 75% inferior a 8000; el
                           grado de sulfatación por unidad de disacárido es aproximadamente 2




manifaxinum
manifaxine                 (2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol

manifaxine                 (2S,3S,5R)-2-(3,5-difluorophényl)-3,5-diméthylmorpholin-2-ol

manifaxina                 (2S,3S,5R)-2-(3,5-difluorofenil)-3,5-dimetilmorfolin-2-ol




98
WHO Drug Information, Vol. 16, No. 1, 2002                                                Recommended INN: List 47




                                     C12H15F2NO2


                                                               CH3
                                                       O        H
                                                  HO
                                      F                       NH

                                                           H CH3

                                              F




miglustatum
miglustat                            (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol

miglustat                            (2R,3R,4R,5S)-1-butyl-2-(hydroxyméthyl)pipéridine-3,4,5-triol

miglustat                            (2R,3R,4R,5S)-1-butil-2-(hidroximetil)piperidina-3,4,5-triol

                                     C10H21NO4


                                                  OH
                                              H        H
                                      HO
                                          H
                                                       N           CH3
                                      HO
                                                       H
                                                       OH




miriplatinum
miriplatin                           (SP-4-2)-[(1R,2R)-cyclohexane-1,2-diamine-N,N]=
                                     bis(tetradecanoato-O)platinum

miriplatine                          (SP-4-2)-[(1R,2R)-cyclohexane-1,2-diamine-N,N]=
                                     bis(tétradécanoato-O)platine

miriplatino                          (SP-4-2)-[(1R,2R)-ciclohexano-1,2-diamina-N,N]=
                                     bis(tetradecanoato-O)platino

                                     C34H68N2O4Pt


                                      H3C                                         O
                                                                                       H2 H
                                                                              O        N
                                                                                  Pt
                                                                              O        N
                                                                                       H2 H
                                      H3 C                                        O




                                                                                                               99
Recommended INN: List 47                                              WHO Drug Information, Vol. 16, No. 1, 2002




mirostipenum
mirostipen                 [23-methionine]human myeloid progenitor inhibitory factor 1-(23-99)-peptide

mirostipen                 [23-méthionine]facteur 1 dinhibition du précurseur myéloïde humain-
                           (23-99)-peptide

mirostipeno                [23-metionina]-(23-99)-péptido del factor 1 de inhibición del progenitor
                           mieloide humano

                           C380H614N112O113S9

                                                                            MDRFHATS             ADCCISYTPR
                           SIPCSLLESY           FETNSECSKP             GVIFLTKKGR                RFCANPSDKQ
                           VQVCMRMLKL           DTRIKTRKN




mureletecanum
mureletecan                poly[[N-(2-hydroxypropyl)methacrylamide]-co-[camptothecin ester with
                           N-[6-(2-methacrylamidoacetamido)hexanoyl]glycine]-co-[N-[[(2-
                           hydroxypropyl)carbamoyl]methyl]methacrylamide]]

murélétécan                copolymère de N-[(2RS)-2-hydroxypropyl]-2-méthylpropénamide, de
                           N-[2-[[6-[[2-[[(4S)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-
                           1H-pyrano[3,4:6,7]indolizino[1,2-b]quinoléin-4-yl]oxy]-2-oxoéthyl]amino]-
                           6-oxohexyl]amino]-2-oxoéthyl]-2-méthylpropénamide et de
                           N-[2-[[(2RS)-2-hydroxypropyl]amino]-2-oxoéthyl]-2-méthylpropénamide

mureletecán                poli[[N-(2-hidroxipropil)metacrilamida]-co-[ éster de camptotecina con
                           N-[6-(2-metacrilamidoacetamido)hexanoil]glicina]-co-[N-[[(2-
                           hidroxipropil)carbamoil]metil]metacrilamida]]


                                                O

                                            N           O

                                                            O
                                      N             O       CH3
                                                                  O
                                                    O   HN
                                                                                                           CH3
                                                                                                 HO
                                                             H3C
                                                                       OH           NH
                                                                                         O            HN
                                                                                                             O
                                                                   NH
                                                            O       CH3              NH
                                                                                O     CH3                  NH
                                                                                                  O         CH3
                                                                            x
                                                                                             y
                                                                                                                  z




100
WHO Drug Information, Vol. 16, No. 1, 2002                                                            Recommended INN: List 47




nasaruplasum beta
nasaruplase beta                     prourokinase (enzyme-activating) human (clone pUK4/pUK18 protein moiety),
                                     glycosylated (murine cell line SP2/0)

nasaruplase bêta                     prourokinase (activateur denzyme) humaine glycosylée dont le gène est
                                     cloné dans le vecteur pUK4/pUK18 et exprimée dans la lignée cellulaire
                                     murine SP2/0

nasaruplasa beta                     prourokinasa (activador de enzima) humana glicosilada cuyo gen se clona en
                                     el vector pUK4/pUK18 y se expresa en la línea celular murina SP2/0

                                     C2031H3121N585O601S31


                                                                     *
                                      SNELHQVPSN              CDCLNGGTCV             SNKYFSNIHW            CNCPKKFGGQ
                                      HCEIDKSKTC              YEGNGHFYRG             KASTDTMGRP            CLPWNSATVL
                                      QQTYHAHRSD              ALQLGLGKHN             YCRNPDNRRR            PWCYVQVGLK
                                      PLVQECMVHD              CADGKKPSSP             PEELKFQCGQ             KTLRPRFKII
                                      GGEFTTIENQ              PWFAAIYRRH             RGGSVTYVCG             GSLISPCWVI
                                      SATHCFIDYP              KKEDYIVYLG             RSRLNSNTQG            EMKFEVENLI
                                      LHKDYSADTL              AHHNDIALLK             IRSKEGRCAQ            PSRTIQTICL
                                                                                       *
                                      PSMYNDPQFG              TSCEITGFGK             ENSTDYLYPE             QLKMTVVKLI
                                      SHRECQQPHY              YGSEVTTKML             CAADPQWKTD            SCQGDSGGPL
                                      VCSLQGRMTL              TGIVSWGRGC             ALKDKPGVYT            RVSHFLPWIR
                                      SHTKEENGLA              L
                                             * : glycosylation sites / sites de glycosylation / posiciones de glicosilación




netoglitazonum
netoglitazone                        (5RS)-5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]thiazolidine-
                                     2,4-dione

nétoglitazone                        (5RS)-5-[[6-[(2-fluorophényl)méthoxy]naphtalén-2-yl]méthyl]thiazolidine-
                                     2,4-dione

netoglitazona                        (5RS)-5-[[6-[(2-fluorofenil)metoxi]naftalen-2-il]metil]tiazolidina-2,4-diona

                                     C21H16FNO3S




                                                      O
                                                                                O      and enantiomer
                                         F                                             et énantiomère
                                                                           S           y enantiómero
                                                                                  NH

                                                                           H     O



                                                                                                                              101
Recommended INN: List 47                                           WHO Drug Information, Vol. 16, No. 1, 2002




ospemifenum
ospemifene                 2-[p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]ethanol

ospémifène                 (Z)-2-[4-(4-chloro-1,2-diphénylbut-1-ényl)phénoxy]éthanol

ospemifeno                 2-[p-[(Z)-4-cloro-1,2-difenil-1-butenil]fenoxi]etanol

                           C24H23ClO2




                                                      O
                                                              OH

                           Cl




pegfilgrastimum
pegfilgrastim              N-(3-hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with
                           α-methyl-ω-hydroxypoly(oxyethylene)

pegfilgrastim              N-(3-hydroxypropyl)méthionylfacteur de stimulation de colonie humain,
                           1-éther avec le α-méthyl-ω-hydroxypoly(oxyéthylène)

pegfilgrastim              N-(3-hidroxipropil)metionilfactor de estimulación de colonias humano, 1-éter
                           con el α-metil-ω-hidroxipoli(oxietileno)

                           C849H1347N223O244S9,(C2H4O)n


                                                                        H3 C          O
                                                                               O     n
                                                                                                 M
                           TPLGPASSLP          QSFLLKCLEQ          VRKIQGDGAA       LQEKLCATYK
                           LCHPEELVLL          GHSLGIPWAP          LSSCPSQALQ       LAGCLSQLHS
                           GLFLYQGLLQ          ALEGISPELG          PTLDTLQLDV       ADFATTIWQQ
                           MEELGMAPAL          QPTQGAMPAF          ASAFQRRAGG       VLVASHLQSF
                           LEVSYRVLRH           LAQP



pexelizumabum
pexelizumab                immunoglobulin, anti-(human complement C5 α-chain) (human-mouse
                           monoclonal 5G1.1-SC single chain)

pexélizumab                immunoglobuline, anti-(chaîne-α du complément C5 humain) (mono chaîne de
                           lanticorps monoclonal de souris humanisé 5G1.1-SC)

pexelizumab                inmunoglobulina, anti-(cadena-α del complemento C5 humano) (mono cadena
                           del anticuerpo monoclonal humanizado de ratón 5G1.1-SC)




102
WHO Drug Information, Vol. 16, No. 1, 2002                                                    Recommended INN: List 47




pralnacasanum
pralnacasan                          (1S,9S)-N-[(2R,3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl]-9-[(isoquinolin-
                                     1-ylcarbonyl)amino]-6,10-dioxooctahydro-6-H-pyridazino[1,2-a][1,2]=
                                     diazepine-1-carboxamide

pralnacasan                          (1S,9S)-N-[(2R,3S)-2-éthoxy-5-oxotétrahydrofuran-3-yl]-9-[(isoquinoléin-
                                     1-ylcarbonyl)amino]-6,10-dioxooctahydro-6-H-pyridazino[1,2-a]=
                                     [1,2]diazépine-1-carboxamide

pralnacasán                          (1S,9S)-N-[(2R,3S)-2-etoxi-5-oxotetrahidrofuran-3-il]-9-[(isoquinolin-
                                     1-ilcarbonil)amino]-6,10-dioxooctahidro-6-H-piridazino[1,2-a][1,2]diazepina-
                                     1-carboxamida

                                     C26H29N5O7




                                                                      H               O
                                                                 O    N
                                                     H H    O
                                                     N           H    H           O
                                         N                                H
                                                                 N            O
                                                 O
                                                                 N
                                                                                  CH3

                                                            O

pratosartanum
pratosartan                          2-propyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-
                                     5,6,7,8-tetrahydrocycloheptaimidazol-4(3H)-one

pratosartan                          2-propyl-3-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-
                                     5,6,7,8-tétrahydrocycloheptaimidazol-4(3H)-one

pratosartán                          2-propil-3-[[2'-(1H-tetrazol-5-il)bifenil-4-il]metil]-
                                     5,6,7,8-tetrahidrocicloheptaimidazol-4(3H)-ona

                                     C25H26N6O


                                                     O
                                                                      N N
                                                                     HN       N
                                                     N
                                             N

                                                           CH3


ragaglitazarum
ragaglitazar                         (-)-(2S)-2-ethoxy-3-[4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl]propanoic
                                     acid

ragaglitazar                         (-)-acide (2S)-2-éthoxy-3-[4-[2-(10H-phénoxazin-10-yl)éthoxy]phényl]=
                                     propanoïque

ragaglitazar                         (-)-ácido (2S)-2-etoxi-3-[4-[2-(10H-fenoxazin-10-il)etoxi]fenil]propanoico




                                                                                                                  103
Recommended INN: List 47                                                WHO Drug Information, Vol. 16, No. 1, 2002




                           C25H25NO5



                                                          O               CH3
                                          N                       H O
                              O
                                                                    CO2H




reslizumabum
reslizumab                 immunoglobulin G4, anti-(human interleukin 5) (human-rat monoclonal
                           SCH 55700 γ4-chain), disulfide with human-rat monoclonal SCH 55700 light
                           chain, dimer

reslizumab                 immunoglobuline G4, anti-(interleukine 5 humaine ), (chaîne γ4 de lanticorps
                           monoclonal de rat humanisé SCH 55700), dimère du disulfure avec la chaîne
                           légère de lanticorps monoclonal de rat humanisé SCH 55700

reslizumab                 immunoglobulina G4, anti-(interleukina 5 humana ), (cadena γ4 del anticuerpo
                           monoclonal humanizado de rata SCH 55700), dímero del disulfuro con la
                           cadena ligera del anticuerpo monoclonal humanizado de rata SCH 55700




ruboxistaurinum
ruboxistaurin              (9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,19H-5,21:12,17-
                           dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-
                           18,20-dione

ruboxistaurine             (9S)-9-[(diméthylamino)méthyl]-6,7,10,11-tétrahydro-9H,19H-5,21:12,17-
                           diméthénodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadécène-
                           18,20-dione

ruboxistaurina             (9S)-9-[(dimetilamino)metil]-6,7,10,11-tetrahidro-9H,19H-5,21:12,17-
                           dimetenodibenzo[e,k]pirrolo[3,4-h][1,4,13]oxadiazaciclohexadeceno-
                           18,20-diona

                           C28H28N4O3


                                                  H
                                      O           N           O




                                          N               N


                                  CH3
                                  N                   O
                           H3C
                                              H




104
WHO Drug Information, Vol. 16, No. 1, 2002                                                   Recommended INN: List 47




semaxanibum
semaxanib                            3-[(Z)-(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone

sémaxanib                            (Z)-3-[(3,5-diméthyl-1H-pyrrol-2-yl)méthylène]-1,3-dihydro-2H-indol-2-one

semaxanib                            3-[(Z)-(3,5-dimetilpirrol-2-il)metileno]-2-indolinona

                                     C15H14N2O


                                                                CH3
                                                      O
                                             HN           HN



                                                               CH3




senazodanum
senazodan                            6-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydropyridazin-3(2H)-one

sénazodan                            6-[4-(pyridin-4-ylamino)phényl]-4,5-dihydropyridazin-3(2H)-one

senazodán                            6-[4-(piridin-4-ilamino)fenil]-4,5-dihidropiridazin-3(2H)-ona

                                     C15H14N4O


                                                                     H
                                                                     N   O
                                                                N

                                      N

                                                  N
                                                  H



silodosinum
silodosin                            (-)-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]=
                                     ethyl]amino]propyl]-2,3-dihydro-1H-indole-7-carboxamide

silodosine                           (-)-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroéthoxy)phénoxy]=
                                     éthyl]amino]propyl]-2,3-dihydro-1H-indole-7-carboxamide

silodosina                           (-)-1-(3-hidroxipropil)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroetoxi)fenoxi]etil]=
                                     amino]propil]-2,3-dihidro-1H-indol-7-carboxamida

                                     C25H32F3N3O4


                                                                                O
                                                                    H
                                                                    N
                                                          O                         NH2
                                      F3C         O                  H CH3
                                                                                N
                                                                                             OH



                                                                                                                    105
Recommended INN: List 47                                        WHO Drug Information, Vol. 16, No. 1, 2002




solifenacinum
solifenacin                (3R)-1-azabicyclo[2.2.2]oct-3-yl (1S)-1-phenyl-3,4-dihydroisoquinoline-
                           2(1H)-carboxylate

solifénacine               (1S)-1-phényl-3,4-dihydroisoquinoléine-2(1H)-carboxylate de
                           (3R)-1-azabicyclo[2.2.2]oct-3-yle

solifenacina               (1S)-1-fenil-3,4-dihidroisoquinolina-2(1H)-carboxilato de
                           (3R)-1-azabiciclo[2.2.2]oct-3-ilo

                           C23H26N2O2




                                        H   O
                                                H
                                        N       O
                                                         N


tadalafilum
tadalafil                  (6R,12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl-
                           2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione

tadalafil                  (6R,12aR)-6-(1,3-benzodioxol-5-yl)-2-méthyl-
                           2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione

tadalafilo                 (6R,12aR)-6-(1,3-benzodioxol-5-il)-2-metil-
                           2,3,6,7,12,12a-hexahidropirazino[1',2':1,6]pirido[3,4-b]indol-1,4-diona

                           C22H19N3O4

                                                O
                                            H
                                                        CH 3
                                                    N
                                            N
                                  N
                                  H
                                            H   O
                              O

                                  O

tafluposidum
tafluposide                4-[(5R,5aR,8aR,9S)-9-[[4,6-O-[(1R)-ethylidene]-
                           2,3-bisO-[(pentafluorophenoxy)acetyl]-β- D-glucopyranosyl]oxy]-6-oxo-
                           5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-5-yl]-
                           2,6-dimethoxyphenyle dihydrogen phosphate

tafluposide                dihydrogénophosphate de 4-[(5R,5aR,8aR,9S)-9-[[4,6-O-[(1R)-éthylidène]-
                           2,3-bisO-[(pentafluorophénoxy)acétyl]-β-D-glucopyranosyl]oxy]-6-oxo-
                           5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphto[2,3-d]-1,3-dioxol-5-yl]-
                           2,6-diméthoxyphényle

taflupósido                dihidrógenofosfato de 4-[(5R,5aR,8aR,9S)-9-[[4,6-O-[(1R)-etilideno]-
                           2,3-bisO-[(pentafluorofenoxi)acetil]-β-D-glucopiranosil]oxi]-6-oxo-
                           5,5a,6,8,8a,9-hexahidrofuro[3',4':6,7]nafto[2,3-d]-1,3-dioxol-5-il]-
                           2,6-dimetoxifenilo




106
WHO Drug Information, Vol. 16, No. 1, 2002                                                                  Recommended INN: List 47




                                     C45H35F10O20P


                                                             F
                                                     F                F
                                                                                   O
                                                     F                F                    O

                                                 O           O
                                                                  H
                                        H                O O
                                                                  H                    H
                                      H3C            O       O                                     OCH3
                                                 O                                 H                   O
                                                                      O
                                                     O   O                                         O   P OH
                                                                               O
                                                                                           OCH 3       OH
                                                     O
                                             F               F


                                             F               F
                                                     F



telberminum
telbermin                            vascular endothelial growth factor (human), dimer

telbermine                           facteur de croissance de lendothélium vasculaire humain (dimère)

telbermina                           factor de crecimiento del endotelio vascular (humano), dímero

                                     C1612H2536N500O498S44



                                       APMAEGGGQN                HHEVVKFMDV                    YQRSYCHPIE       TLVDIFQEYP

                                       DEIEYIFKPS                CVPLMRCGGC                    CNDEGLECVP       TEESNITMQI

                                       MRIKPHQGQH                IGEMSFLQHN                    KCECRPKKDR ARQENPCGPC

                                       SERRKHLFVQ                DPQTCKCSCK NTDSRCKARQ                          LELNERTCRC

                                       DKPRR                                                                                 2

                                                                          : disulfide / disulfure / disulfuro



tenivastatinum
tenivastatin                         (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl-
                                     1,2,6,7,8,8a-hexahydronaphtalen-1-yl]-3,5-dihydroxyheptanoic acid

ténivastatine                        acide (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-[(2,2-diméthylbutanoyl)oxy]-
                                     2,6-diméthyl-1,2,6,7,8,8a-hexahydronaphtalén-1-yl]-
                                     3,5-dihydroxyheptanoïque

tenivastatina                        ácido (3R,5R)-7-[(1S,2S,6R,8S,8aR)-8-[(2,2-dimetilbutanoil)oxi]-2,6-dimetil-
                                     1,2,6,7,8,8a-hexahidronaftalen-1-il]-3,5-dihidroxiheptanoico



                                                                                                                                 107
Recommended INN: List 47                                            WHO Drug Information, Vol. 16, No. 1, 2002




                           C25H40O6


                               CH3                          CO2H
                                             H OH
                           H     H
                                                               OH
                                         H                 H
                                             O        O
                                             H
                                                          CH3
                                         H 3C
                                                 CH3
                                 H CH3




tesaglitazarum
tesaglitazar               (2S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]phenyl]=
                           propanoic acid

tésaglitazar               acide (2S)-2-éthoxy-3-[4-[2-[4-[(méthylsulfonyl)oxy]phényl]éthoxy]phényl]=
                           propanoïque

tesaglitazar               ácido (2S)-2-etoxi-3-[4-[2-[4-[(metilsulfonil)oxi]fenil]etoxi]fenil]propanoico

                           C20H24O7S


                                                                O             CH3
                              O O                                     H O
                               S
                           H3C   O                                         CO2H




tofimilastum
tofimilast                 9-cyclopentyl-7-ethyl-3-(thiophen-2-yl)-6,9-dihydro-5H-pyrazolo[3,4-c]-
                           1,2,4-triazolo[4,3-a]pyridine

tofimilast                 9-cyclopentyl-7-éthyl-3-(thiophén-2-yl)-6,9-dihydro-5H-pyrazolo[3,4-c]-
                           1,2,4-triazolo[4,3-a]pyridine

tofimilast                 9-ciclopentil-7-etil-3-(tiofen-2-il)-6,9-dihidro-5H-pirazolo[3,4-c]-
                           1,2,4-triazolo[4,3-a]piridina

                           C18H21N5S




                                                 N N
                                     N
                                                  N
                                 N                          S


                           H3C




108
WHO Drug Information, Vol. 16, No. 1, 2002                                              Recommended INN: List 47




xidecaflurum
xidecaflur                           2,2-[(9Z)-9-octadecenylimino]diethanol hydrofluoride

xidécaflur                           fluorhydrate de 2,2-[(9Z)-octadec-9-énylimino]diéthanol

xidecaflur                           hidrofluoruro de 2,2 -[(9Z)-9-octadecenilimino]dietanol

                                     C22H46FNO2

                                      H3C                                                             OH
                                                                                               N            , HF
                                                                                                   OH




zanapezilum
zanapezil                            3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-
                                     8-yl)propan-1-one

zanapézil                            3-(1-benzylpipéridin-4-yl)-1-(2,3,4,5-tétrahydro-1H-1-benzazépin-
                                     8-yl)propan-1-one

zanapezilo                           3-(1-bencilpiperidin-4-il)-1-(2,3,4,5-tetrahidro-1H-1-benzazepin-8-il)propan-
                                     1-ona

                                     C25H32N2O

                                                      O



                                                                     N

                                                 NH




zonampanelum
zonampanel                           [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-
                                     1(2H)-yl]acetic acid

zonampanel                           acide [7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-
                                     1(2H)-yl]acétique

zonampanel                           ácido [7-(1H-imidazol-1-il)-6-nitro-2,3-dioxo-3,4-dihidroquinoxalin-
                                     1(2H)-il]acético

                                     C13H9N5O6
                                                              CO2H

                                      N
                                             N            N     O


                                          O2N             N     O
                                                          H




                                                                                                                   109
Recommended INN: List 47                                                     WHO Drug Information, Vol. 16, No. 1, 2002




zoniporidum
zoniporide                 N-carbamimidoyl-5-cyclopropyl-1-(quinolin-5-yl)-1H-pyrazole-4-carboxamide

zoniporide                 N-carbamimidoyl-5-cyclopropyl-1-(quinoléin-5-yl)-1H-pyrazole-
                           4-carboxamide

zoniporida                 N-carbamimidoil-5-ciclopropil-1-(quinolin-5-il)-1H-pyrazol-4-carboxamida

                           C17H16N6O

                                                   O       NH

                                                       N           NH2
                                       N               H
                                           N


                               N




zoticasonum
zoticasone                 S-[(3R)-2-oxotetrahydrofuran-3-yl] 6α,9-difluoro-12β,17-dihydroxy-
                           16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate

zoticasone                 6α,9-difluoro-12β,17-dihydroxy-16α-méthyl-3-oxoandrosta-1,4-diène-
                           17β-carbothioate de S-[(3R)-2-oxotétrahydrofuran-3-yle]

zoticasona                 6α,9-difluoro-12β,17-dihidroxi-16α-metil-3-oxoandrosta-1,4-dieno-
                           17β-carbotioato de S-[(3R)-2-oxotetrahidrofuran-3-ilo]

                           C25H30F2O6S



                                                                         O
                                                           H
                                                       O
                                                               S         O
                                           H       CH3
                                   HO                      OH
                                   CH3         H             CH3
                                                           H
                                           F       H
                           O
                                       H       F




110
WHO Drug Information, Vol. 16, No. 1, 2002                                           Recommended INN: List 47




                             AMENDMENTS TO PREVIOUS LISTS
                     MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                         MODIFICACIONES A LAS LISTAS ANTERIORES


Proposed International Nonproprietary Names (Prop. INN): List 59
Dénominations communes internationales proposées (DCI Prop.): Liste 59
Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 59
(WHO Drug Information/Informations pharmaceutiques OMS/Informaciones farmaceuticas de la OMS,
Vol. 2, No. 2, 1988)

p. 16   delete/supprimer/suprimase    insert/insérer/insértese

        levoglutamidum                glutaminum
        levoglutamide                 glutamine
        lévoglutamide                 glutamine
        levoglutamida                 glutamina



Recommended International Nonproprietary Names (Rec. INN): List 42
Dénominations communes internationales recommendées (DCI Rec.): Liste 42
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 42
(WHO Drug Information, Vol. 13, No. 3, 1999)

        suprimase                     insértese

p. 184 carabersato                    carabersat

p. 207 tonabersato                    tonabersat



Recommended International Nonproprietary Names (Rec. INN): List 44
Dénominations communes internationales recommendées (DCI Rec.): Liste 44
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 44
(WHO Drug Information, Vol. 14, No. 3, 2000)

p. 199 delete/supprimer/suprimase     insert/insérer/insértese

        nebostinelum                  neboglaminum
        nebostinel                    neboglamine
        nébostinel                    néboglamine
        nebostinel                    neboglamina


p. 199 onerceptum
       onercept                       replace the description by the following:
                                      TNF-BP-(20-180)-peptide (part of extracellular domain of the glycosylated
                                      human Tumor Necrosis Factor Receptor 1)

        onercept                      sustitúyase la descripción por la siguiente:
                                      péptido (20-180) TNF-BP (parte del dominio extracelular del receptor 1
                                      humano del factor de necrosis tumoral glicosilado)




                                                                                                               111
Recommended INN: List 47                                                   WHO Drug Information, Vol. 16, No. 1, 2002




Recommended International Nonproprietary Names (Rec. INN): List 45
Dénominations communes internationales recommendées (DCI Rec.): Liste 45
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 45
(WHO Drug Information, Vol. 15, No. 1, 2001)

p. 55   evernimicinum
        evernimicina                    sustitúyase la descripción por la siguiente:
                                        O-3-C-metil-4-O-metil-3-nitro-2,3,6-tridesoxi-α-L -arabino-hexopiranosil-
                                        (1→3)-O-4-O-(3,5-dicloro-4-hidroxi-2-metoxi-6-metilbenzoil)-2,6-didesoxi-
                                        β-D-arabino-hexopiranosil-(1→4)-O-(1R)-2,6-didesoxi- D-arabino-
                                        hexopiranosilideno-(1→3-4)-O-3-C-metil-6-desoxi-β- D-manopiranosil-
                                        (1→3)-O-4-O-metil-6-desoxi-β-D-galactopiranosil-(1→4)-2,6-di-O-metil-
                                        β-D-manopiranosido de O-(1R)-4-O-(2,4-dihidroxi-6-metilbenzoil)-
                                        2,3-O-metileno-D-xilopiranosilideno-(1→3-4)-α-L-lixopiranosilo




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in uneven numbers of proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour
les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internatio-
nales applicables aux substances pharmaceutiques seront publiés seulement dans les numéros impaires des listes
des DCIs proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las
sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes
internacionales para sustancias farmacéuticas aparece solamente en los números impares de las listas de DCI propuestas.



112
